Published in Transplantation on October 15, 1998
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood (2007) 1.36
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant (2015) 1.12
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 0.95
Psychosocial factors and hematopoietic stem cell transplantation: potential biobehavioral pathways. Psychoneuroendocrinology (2013) 0.94
Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant (2009) 0.91
Biologic markers of chronic GVHD. Bone Marrow Transplant (2013) 0.91
Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica (2011) 0.87
Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality. Biol Blood Marrow Transplant (2009) 0.78
Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol (2011) 0.77
Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target. Front Immunol (2017) 0.75
A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res (2016) 0.75
Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Biol Blood Marrow Transplant (2017) 0.75
Y-antigen killing by T cells of women is restricted by HLA. Nature (1977) 2.73
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet (2005) 2.45
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science (1998) 2.11
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int (2006) 1.92
The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity (1997) 1.78
Testing the fit of a regression model via score tests in random effects models. Biometrics (1995) 1.76
Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature (1992) 1.76
Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg (1994) 1.74
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol (1999) 1.68
T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation. Eur J Immunol (1986) 1.62
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol (1992) 1.55
Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol (1999) 1.44
Permanent detrimental effect of nonimmunological factors on long-term renal graft survival: a parsimonious model of time-dependency. Transplantation (2000) 1.42
Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol (1999) 1.38
A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature (1983) 1.34
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J (2001) 1.28
Cell-mediated lympholysis studies in renal allograft recipients. Transplantation (1981) 1.25
Score test for linkage in generalized linear models. Hum Hered (2007) 1.23
Diurnal variation in lung function in subgroups from two Dutch populations: consequences for longitudinal analysis. Am J Respir Crit Care Med (1999) 1.21
Alloimmunity to human H-Y. Lancet (1976) 1.20
Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet (1990) 1.19
Genomic identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR. Tissue Antigens (1998) 1.18
The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol (2001) 1.14
Cerebral microbleeds in CADASIL. Neurology (2001) 1.13
Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J Gen Virol (1995) 1.12
Anti-self HLA may be clonally expressed. J Exp Med (1979) 1.10
Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics (1992) 1.10
Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood (1994) 1.08
Time-dependent effects of fixed covariates in Cox regression. Biometrics (1995) 1.08
Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res (1990) 1.07
Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells. J Clin Invest (1988) 1.05
The importance of H-Y incompatibility in human organ transplantation. Transplantation (1978) 1.03
Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. J Exp Med (1988) 1.03
Existence of mature human CD4+ T cells with genuine class I restriction. Eur J Immunol (1992) 1.02
Testing familial aggregation. Biometrics (1995) 1.02
HLA restriction of non-HLA--A, --B, --C and --D cell mediated lympholysis (CML). Tissue Antigens (1976) 1.01
Analysis of the renal transplant waiting list: application of a parametric competing risk method. Transplantation (1998) 1.00
Major histocompatibility complex-restricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. J Exp Med (1979) 0.99
Score test for age at onset genetic linkage analysis in selected sibling pairs. Stat Med (2009) 0.98
Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol (1997) 0.97
Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation (1999) 0.95
Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics (1993) 0.94
Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet (1996) 0.93
Surgery groups differed in adverse outcome probabilities and can be used to adjust hospital comparisons. J Clin Epidemiol (2005) 0.93
Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia (2006) 0.93
Typing for MLC (LD). I. Lymphocytes from cousin-marriage offspring as typing cells. Transplant Proc (1973) 0.92
Much ado about minor histocompatibility antigens. Immunol Today (1998) 0.92
New facts on HLA genetics: are they relevant in bone marrow transplantation? Semin Hematol (1984) 0.92
Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys (1999) 0.91
Class-I-restricted human cytotoxic T lymphocytes directed against minor transplantation antigens and their possible role in organ transplantation. Prog Allergy (1985) 0.91
Isolation of an HLA-A2.1 extracted human minor histocompatibility peptide. Eur J Immunol (1993) 0.90
Major histocompatibility complex-restricted H-Y-specific antibodies and cytotoxic T lymphocytes may recognize different self determinants. J Exp Med (1982) 0.89
Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. I. Population studies. Immunogenetics (1982) 0.89
Acute graft versus host disease due to T lymphocytes recognizing a single HLA-DPB1*0501 mismatch. J Clin Invest (1996) 0.89
Prevalence of deep vein thrombosis in suspected and proven pulmonary embolism: a meta-analysis. Br J Radiol (1998) 0.88
Do noninherited maternal antigens (NIMA) enhance renal graft survival? Transpl Int (1998) 0.87
Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost (1998) 0.87
Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia (2010) 0.87
Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest (1995) 0.86
Production, expansion, and clonal analysis of T cells with specific HLA-restricted male lysis. J Exp Med (1980) 0.85
In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant (1992) 0.85
T lymphocyte cloning from rejected human kidney allograft. Recognition repertoire of alloreactive T cell clones. J Immunol (1988) 0.85
Month-related variability in immunological test results; implications for immunological follow-up studies. Clin Exp Immunol (1991) 0.84
Separation of the genetic loci for the H-Y antigen and for testis determination on human Y chromosome. Nature (1987) 0.84
Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. II. Definition of three HLA-A2 subtypes by CTLs. Immunogenetics (1983) 0.84
The association between human leucocyte antigens (HLA) and mortality in community residents aged 85 and older. J Am Geriatr Soc (1997) 0.83
Susceptibility of human male keratinocytes to MHC-restricted H-Y-specific lysis. J Exp Med (1989) 0.83
A genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent of HLA. Immunogenetics (1993) 0.83
Estimation of individual genetic effects from binary observations on relatives applied to a family history of respiratory illnesses and chronic lung disease of newborns. Biometrics (2000) 0.83
A polygenic model for integration of linkage and pathway information. Genet Epidemiol (2009) 0.83
Mortality rates after heart transplantation: how to compare center-specific outcome data? Transplantation (2003) 0.83
Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. I. Absence of correlation with cytotoxic effector cells. Transplantation (1990) 0.83
HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells. Blood (1997) 0.83
The (in)validity of sensitivity and specificity. Stat Med (2000) 0.83
Cell-mediated lysis of human hematopoietic progenitor cells. Leukemia (1987) 0.82
H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births. Hum Reprod (2010) 0.82
HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation (1998) 0.82
Human minor histocompatibility antigens. Transpl Immunol (1993) 0.82
Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone. Thromb Haemost (1985) 0.81
14thInternational HLA and Immunogenetics Workshop: report on hematopoietic cell transplantation. Tissue Antigens (2007) 0.81
The effects of stress and relaxation on the in vitro immune response in man: a meta-analytic study. J Behav Med (1993) 0.81
HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. Hematol J (2000) 0.81
Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells. Eur J Immunol (1991) 0.81
Role of the HLA system in transplantation. HLA compatibility in clinical transplantation. Transplant Proc (1977) 0.80
Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens. II. Evidence of a possible involvement of proliferative T cells. Transplantation (1990) 0.80
Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease. Bone Marrow Transplant (1997) 0.80